Skip to contentpdufa.bio

DNL952

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

DNL952 is a Denali Therapeutics Inc. program in late-onset Pompe disease (LOPD). Its next catalyst is a Readout in Q4 2027.

DNLI catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Late-onset Pompe disease (LOPD). Sponsor: Denali Therapeutics Inc. (DNLI). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027DNLI

Specialist biotech funds holding DNLI, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors3,734,336$77.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is DNL952's next FDA decision or readout?

The next tracked catalyst for DNL952 is a Readout in Q4 2027.

What happened at DNL952's most recent FDA decision?

No FDA decision for DNL952 is in our archive yet.

What is DNL952 used for?

In our records DNL952 is under review or in development for Late-onset Pompe disease (LOPD).

Who makes DNL952?

Denali Therapeutics Inc. (DNLI).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.